Initial Clinical Experience with Ahmed Valve in Romania: Five-Year Patient Follow-Up and Outcomes.

IF 3.8 3区医学 Q2 ENGINEERING, BIOMEDICAL

Bioengineering Pub Date : 2024-08-12 DOI:10.3390/bioengineering11080820

Ramona Ileana Barac, Vasile Harghel, Nicoleta Anton, George Baltă, Ioana Teodora Tofolean, Christiana Dragosloveanu, Laurențiu Flavius Leuștean, Dan George Deleanu, Diana Andreea Barac

{"title":"Initial Clinical Experience with Ahmed Valve in Romania: Five-Year Patient Follow-Up and Outcomes.","authors":"Ramona Ileana Barac, Vasile Harghel, Nicoleta Anton, George Baltă, Ioana Teodora Tofolean, Christiana Dragosloveanu, Laurențiu Flavius Leuștean, Dan George Deleanu, Diana Andreea Barac","doi":"10.3390/bioengineering11080820","DOIUrl":null,"url":null,"abstract":"Background: Glaucoma is a leading cause of irreversible blindness worldwide and is particularly challenging to treat in its refractory forms. The Ahmed valve offers a potential solution for these difficult cases. This research aims to assess the initial clinical experience with Ahmed valve implantation in Romania, evaluating its effectiveness, associated complications, and overall patient outcomes over a five-year period.Methods: We conducted a prospective study on 50 patients who underwent Ahmed valve implantation due to various types of glaucoma. Patients were monitored at several intervals, up to five years post-surgery. Intraocular pressure and visual acuity were the primary measures of success.Results: On average, patients maintained the intraocular pressure within the targeted range, with the mean intraocular pressure being 17 mmHg 5 years post-surgery. Success, defined as maintaining target intraocular pressure without additional surgery, was achieved in 82% at 1 year, 68% at 3 years, and 60% after 5 years postoperative.Conclusion: Ahmed valve implantation is a viable treatment option for refractory glaucoma, demonstrating significant intraocular pressure reduction and manageable complication rates over a five-year follow-up period. Future research should focus on long-term outcomes and optimization of surgical techniques to further reduce complication rates and improve patient quality of life.","PeriodicalId":8874,"journal":{"name":"Bioengineering","volume":null,"pages":null},"PeriodicalIF":3.8000,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11351579/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioengineering","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3390/bioengineering11080820","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Glaucoma is a leading cause of irreversible blindness worldwide and is particularly challenging to treat in its refractory forms. The Ahmed valve offers a potential solution for these difficult cases. This research aims to assess the initial clinical experience with Ahmed valve implantation in Romania, evaluating its effectiveness, associated complications, and overall patient outcomes over a five-year period.

Methods: We conducted a prospective study on 50 patients who underwent Ahmed valve implantation due to various types of glaucoma. Patients were monitored at several intervals, up to five years post-surgery. Intraocular pressure and visual acuity were the primary measures of success.

Results: On average, patients maintained the intraocular pressure within the targeted range, with the mean intraocular pressure being 17 mmHg 5 years post-surgery. Success, defined as maintaining target intraocular pressure without additional surgery, was achieved in 82% at 1 year, 68% at 3 years, and 60% after 5 years postoperative.

Conclusion: Ahmed valve implantation is a viable treatment option for refractory glaucoma, demonstrating significant intraocular pressure reduction and manageable complication rates over a five-year follow-up period. Future research should focus on long-term outcomes and optimization of surgical techniques to further reduce complication rates and improve patient quality of life.

查看原文本刊更多论文

罗马尼亚使用艾哈迈德瓣膜的初步临床经验：五年患者随访及结果。

背景：青光眼是导致全球不可逆失明的主要原因之一，其难治性尤其具有挑战性。艾哈迈德瓣膜为这些疑难病例提供了潜在的解决方案。本研究旨在评估在罗马尼亚进行艾哈迈德瓣膜植入术的初步临床经验，评价其有效性、相关并发症以及五年内患者的总体疗效：我们对 50 名因各种类型的青光眼而接受艾哈迈德瓣膜植入术的患者进行了前瞻性研究。我们在手术后的五年内对患者进行了多次监测。眼压和视力是衡量手术成功与否的主要指标：结果：平均而言，患者的眼压保持在目标范围内，术后 5 年的平均眼压为 17 mmHg。术后 1 年成功率为 82%，3 年成功率为 68%，5 年后成功率为 60%：艾哈迈德瓣膜植入术是治疗难治性青光眼的一种可行方法，在五年的随访期间，眼压明显下降，并发症发生率也在可控范围内。未来的研究应侧重于长期疗效和手术技术的优化，以进一步降低并发症发生率，提高患者的生活质量。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Bioengineering Chemical Engineering-Bioengineering

CiteScore

4.00

自引率

8.70%

发文量

661

期刊介绍： Aims Bioengineering (ISSN 2306-5354) provides an advanced forum for the science and technology of bioengineering. It publishes original research papers, comprehensive reviews, communications and case reports. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. All aspects of bioengineering are welcomed from theoretical concepts to education and applications. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. There are, in addition, four key features of this Journal: ● We are introducing a new concept in scientific and technical publications “The Translational Case Report in Bioengineering”. It is a descriptive explanatory analysis of a transformative or translational event. Understanding that the goal of bioengineering scholarship is to advance towards a transformative or clinical solution to an identified transformative/clinical need, the translational case report is used to explore causation in order to find underlying principles that may guide other similar transformative/translational undertakings. ● Manuscripts regarding research proposals and research ideas will be particularly welcomed. ● Electronic files and software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material. ● We also accept manuscripts communicating to a broader audience with regard to research projects financed with public funds. Scope ● Bionics and biological cybernetics: implantology; bio–abio interfaces ● Bioelectronics: wearable electronics; implantable electronics; “more than Moore” electronics; bioelectronics devices ● Bioprocess and biosystems engineering and applications: bioprocess design; biocatalysis; bioseparation and bioreactors; bioinformatics; bioenergy; etc. ● Biomolecular, cellular and tissue engineering and applications: tissue engineering; chromosome engineering; embryo engineering; cellular, molecular and synthetic biology; metabolic engineering; bio-nanotechnology; micro/nano technologies; genetic engineering; transgenic technology ● Biomedical engineering and applications: biomechatronics; biomedical electronics; biomechanics; biomaterials; biomimetics; biomedical diagnostics; biomedical therapy; biomedical devices; sensors and circuits; biomedical imaging and medical information systems; implants and regenerative medicine; neurotechnology; clinical engineering; rehabilitation engineering ● Biochemical engineering and applications: metabolic pathway engineering; modeling and simulation ● Translational bioengineering